6533b82efe1ef96bd12934df

RESEARCH PRODUCT

Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group

Alessandro ComandoneJ. Martin BrotoA. P. Dei TosPaolo VerderioPaola ColliniSilvia FerrariStefano BottelliR. De SanctisDavide Maria DonatiAntonio Llombart-boschAndres PovedaA. De PaoliJ. Cruz JuradoGiovanni GrignaniPaolo G. CasaliElena PalassiniAntonio Lopez-pousaAntonella MessinaCarlo MorosiAlessandro GronchiSilvia StacchiottiPiero PicciVittorio Quagliuolo

subject

LeiomyosarcomaMale0301 basic medicinesarcomaSurvivalmedicine.medical_treatment0302 clinical medicineRisk FactorsQuality of surgeryNeoadjuvant therapySoft tissue sarcomaIfosfamideresponseSoft tissue sarcomaResponseSarcomaHematologyMiddle AgedPrognosisadjuvant chemotherapyTreatment OutcomeOncologyChemotherapy Adjuvant030220 oncology & carcinogenesissoft tissue sarcomaFemaleSarcomaadjuvant chemotherapy; quality of surgery; response; sarcoma; soft tissue sarcoma; survivalmedicine.drugEpirubicinAdultLeiomyosarcomamedicine.medical_specialtyPreoperative caresurvivalDisease-Free Survival03 medical and health sciencesmedicineHumansAgedbusiness.industrymedicine.diseaseSurgeryAdjuvant chemotherapyRegimen030104 developmental biologybusinessquality of surgeryFollow-Up Studies

description

[Background] To report on long-term results of a phase 3 trial comparing three versus five cycles of adjuvant chemotherapy (CT) with full-dose epirubicin+ifosfamide in high-risk soft tissue sarcomas (STS).

yearjournalcountryeditionlanguage
2016-12-01
10.1093/annonc/mdw430http://hdl.handle.net/10261/182741